AzTrials
AzTrials

Post CystostomyPhase 4ONPNCT01777126

Oral Nutrition After Regular Radical Cystectomy

A Phase 4 study testing Oral Nutrition Protocol (ONP) group in people with Post Cystostomy, run by Universitaire Ziekenhuizen KU Leuven at 1 site in Belgium.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

After radical cystectomy, postoperative ileus (POI) is a common complication resulting in a delayed oral nutritional intake with prolonged recovery and hospital stay. However, it is questionable if nutritional support by routine use of parenteral nutrition (PN) is justifiable. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Post Cystostomy
What is being tested?
Oral Nutrition Protocol (ONP) group
Could I receive a placebo?
No, everyone receives an active treatment
How many people
94 participants
Where
1 siteBelgium
Study dates
Jan 2009to Nov 2012
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • regular radical cystectomy

Who cannot join

  • preoperative contra-indications for enteral nutrition (EN): intestinal obstruction, malabsorption, multiple high-output fistula and intestinal ischemia

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • University Hospitals Leuven

    Leuven, 3000

Other trials in Belgium

About this study

Official title: A Simple Oral Nutrition Protocol Reduces Length of Stay in Patients With Regular Radical Cystectomy

After radical cystectomy, postoperative ileus (POI) is a common complication resulting in a delayed oral nutritional intake with prolonged recovery and hospital stay. However, it is questionable if nutritional support by routine use of parenteral nutrition (PN) is justifiable.

A non-randomized before-after trial was conducted. Patients treated with an elective regular radical cystectomy and without preoperative contra-indications for enteral nutrition were eligible. In the control group, PN was initiated immediately after the procedure and continued until resumption of diet. In the interventional group, an ONP was implemented. PN could be initiated if oral intake was still insufficient after five days. The primary end point was the postoperative length of stay.

Read the detailed description

Design

A prospective interventional non-randomized before-after trial was conducted. Eligible patients admitted from 01/02/2009 were consecutively assigned to the control group until the predefined sample size was reached. After enrollment and follow-up of control patients had been finished, all newly admitted eligible patients were consecutively assigned to the interventional group.

In addition to the before-after study, a sample of eligible patients was collected from March 2011 to March 2013 (follow-up group) to examine the post-study impact of the ONP.

Patients

All adult patients admitted to the 48-bed urological ward in the 1850 bed University Hospitals Leuven and treated with elective and regular RC, whether or not for underlying cancer, were eligible for inclusion. Three different diversions are performed: an ileal conduit, an orthothopic neobladder (N-pouch)12 or a continent cutaneous diversion. The surgical procedure was considered regular if the patient returned after the procedure to the urological ward and was not transferred to the intensive care unit. If the latter was deemed necessary by the treating surgeon, the patient would be subjected to the intensive care nutrition protocol. Therefore, only regular RC patients were included.

Exclusion criteria were transfer to the intensive care unit, preoperative contra-indications for EN and discharge to a rehabilitation center. Contra-indications for EN were defined as intestinal obstruction, malabsorption, multiple high-output fistula or intestinal ischemia8. Uretero-ileal or ileo-ileal anastomoses, resulting from RC, were not considered as a contra-indication for EN9,10. Discharge to a rehabilitation center could surpass one of the criteria for discharge, i.e. the ability of independent mobilization, and could therefore influence the postoperative LOS.

Care practices other than nutrition management

Preoperatively, all patients received bowel preparation with a 2 liter osmotic laxative (macrogol 3350 100 g, sodiumsulphate 7.5 g, NaCl 2.69 g, KCl 1.02 g, sodium salt of ascorbic acid 5.9 g and ascorbic acid 4.7 g). Before incision, a loading dose of 0.05 ml/cm epidural analgesics (levobupivacaine 2,5 mg/ml and sufentanil 1 mcg/ml) was administered. During surgery, a central venous catheter, a nasogastric or percutaneous gastrostomy tube and ureteral stents were inserted. The nasogastric or percutaneous gastrostomy tube was removed on the first or second postoperative day after restoration of transit (defined as a residual gastric volume of less than 50 ml/24h). Acetaminophen, non-steroidal anti-inflammatory drugs and patient-controlled epidural analgesia (PCEA; levobupivacaine 2,5 mg/ml and sufentanil 1 mcg/ml) were available for postoperative acute pain management. Intraoperative antimicrobial prophylaxis consisted of cefazoline and metronidazole. Thromboprophylaxis consisted of enoxaparin. Anti-emetics and other prokinetic drugs were not routinely administered but only prescribed when needed. All treating surgeons were fully trained at the start of the study.

After a minimum of 10 days, ureteral stents were removed if the following 3 criteria were met: restoration of transit, presence of bowel movements and absence of fever (defined as body temperature <38,3 °C). Prophylactic levofloxacin 500 mg once daily was administered after stent removal, until the first consultation. Patients were discharged if the following 4 criteria were fulfilled: 1) removal of all drains and stents, 2) the absence of fever (body temperature < 38,3 °C), 3) the ability to tolerate solid food and 4) the ability of independent mobilization.

The abovementioned care practices (anesthesia modalities, surgical techniques, doses of narcotics, bowel stimulants and anti-nauseants, and mobilization practices) did not alter during the course of the study.

Nutrition management

In the control group, PN was initiated immediately after surgery and continued until the patient was able to tolerate solid food. PN infusion therapy consisted of Olimel® (Baxter S.A., Lessines, Belgium) N7E 1000 ml, 1500 ml or 2000 ml; a parenteral solution with a total energy of 1100 kcal/1000 ml and containing polyamino-acids (43.75g/1000 ml), glucose (140g/1000ml), lipids (40g/1000ml) and electrolytes. Cernevit® (Baxter S.A., Lessines, Belgium), a multivitamin powder for injection, and Addamel® (Fresenius Kabi, Schelle, Belgium), a concentrate for injection containing trace elements, were added daily to the PN. The amount of PN administered depended on the non-protein requirements, calculated by 30 ± 10% kcal/kg ideal body weight13. Extra fluids, up to two liter per day, were given intravenously, at the discretion of the treating physician.

In the interventional group, the ONP was implemented (Table 1). Oral intake was increased progressively with oral fluids and easily digestible food, independent of bowel movements. The corresponding energy content from the meals and oral fluids were calculated. Fortimel Jucy®, 200 ml containing 300 kcal, was used as the formulary energy sip. Extra fluids, up to two liter per day, were given intravenously, at the discretion of the treating physician. Nurses verified daily whether the patient was able to tolerate the ONP. If the patient tolerated the ONP well, the oral intake was considered equal in terms of calories as the corresponding oral meal in the ONP. From the sixth day, the patient was allowed to eat at will. Only if oral intake remained insufficient after 5 days, which was left to the opinion of the treating physician, PN could be initiated in this group.

Data collection

The following baseline demographic data were retrieved from medical files: patient characteristics (gender, age, weight, length, body mass index, age-adjusted Charlson comorbidity index14, indication for RC (oncologic or neurogenic) and bladder cancer staging (TNM classification15)), surgical aspects (type of urinary diversion, attending surgeon, intra-operative blood loss and duration of procedure), postoperative ileus (POI) and day of nasogastric tube removal. The age-adjusted Charlson comorbidity index is a method for classifying comorbid conditions. As the increase in elderly population and concurrent increase in oncologic disease (and thus in bladder cancer) emphasized the importance of understanding the interaction between age an comorbid illness on life expectancy, the age -adjusted version was used. POI was defined as the inability to tolerate solid food, the need to place a nasogastric tube in suction, the need to stop oral intake due to abdominal distention (evaluated by the treating clinician), nausea or emesis.

Endpoints

The primary endpoint was LOS from surgery to discharge.

Secondary endpoints were the number of patients with successful implementation of the ONP, as well as number of administered PN infusion bags per patient, time to resumption of full diet, number of patients with one or more postoperative complications (POC), number of POCs per patient, type and severity grade of POCs and the incidence of catheter related bloodstream infections (CRBSIs). The implementation of the ONP was considered successful if the protocol could be completely applied and no PN was needed. The type and severity of POCs were classified using the Clavien-Dindo classification16. POCs were classified into 11 categories and stratified by severity. CRBSI, a common PN-related complication6, was defined as bacteremia or fungemia in a patient having an intravascular device and more than one positive blood culture result obtained from a peripheral vein, clinical manifestations of infection (e.g., fever, chills, and/or hypotension) and no apparent other source for blood stream infection17.

Post-study impact

An additional patient cohort was assembled, using the same inclusion and exclusion criteria as described above. The LOS and number of PN infusion bags after surgery were determined and compared to the results obtained from the intervention group.

Analysis of PN associated costs

The avoided PN cost per patient were calculated. For every group, the total number of PN infusion bags was divided by the number of patients and multiplied by € 60, which was the average actual cost in euros of one bag of Olimel® in Belgium at the time of the study. This resulted in a direct and comparable PN infusion bag related cost per patient per group.

Statistical analysis and sample size calculation

Statistical analysis was performed by L-Biostat, Catholic University Leuven, using SPSS package (SPSS Statistics 20.0 for Windows). Chi-square and Fisher's Exact tests were used for categorical data. The unpaired T-test or the Wilcoxon rank sum test was used for normal and non-normal distributed continuous variables respectively. Baseline demographic data and the outcome measures were considered statistically significant if p-values were < 0.05. The Bonferroni correction was used to account for multiple comparisons (6 secondary outcome measures). Therefore, secondary outcome parameters were considered statistically significant if p-values were < 0.008. To asses factors influencing LOS, general linear model statistics - univariate analysis followed by ANOVA - were carried out.

Preliminary data from our institution showed that all RC patients receiving PN directly after surgery were discharged after a mean of 19.3 ± 5.6 days. We expected to reduce our LOS with 3 days from 19 to 16 days by implementing the ONP. Assuming that variances for both groups are comparable, 88 (2x44) patients were needed, giving at least 80 % power (α=0.05, one-tailed) to reject the null hypothesis defined as no difference in postoperative LOS between the two groups.

The study was approved by the hospital's Ethics Committee and registered on clinical trials.gov n° NCT01777126. No informed consent was obtained as the introduction of the ONP was part of continuous improvement of standard of care in our hospital.

Conditions
Post Cystostomy
Being tested
Oral Nutrition Protocol (ONP) group, Control group
Keywords
cystectomy, parenteral nutrition, discharge, outcome
Medical subject headings
Hyperphagia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Oral Nutrition Protocol (ONP) groupOther

    For the experimental group, an oral nutrition protocol (ONP) with restrictive instructions for parenteral nutrition is implemented. Oral intake is increased progressively with oral fluids and easily digestible food, independent of clinical bowel movements. The oral energy sips used are Fortimel Jucy® (Nutricia) 200 ml containing 300 kcal. This provides supplementary energy and essential nutrients. Supplementary fluid, approximately up to two liter, is given intravenously. Only if oral intake is still insufficient after five days, PN (Oliclinomel N7) can be initiated.

  • Control groupOther

    Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.

Study groups in NCT01777126
Study groupRoleWhat they receive
Control groupActive comparatorSubjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
Receives: Other: Control group
Oral Nutrition Protocol (ONP) groupExperimentalOral intake was increased progressively with oral fluids and easily digestible food, independent of bowel movements. The corresponding energy content from the meals and oral fluids were calculated. Fortimel Jucy®, 200 ml containing 300 kcal, was used as the formulary energy sip. Extra fluids, up to two liter per day, were given intravenously, at the discretion of the treating physician. If the patient tolerated the ONP well, the oral intake was considered equal in terms of calories as the corresponding oral meal in the ONP. From the sixth day, the patient was allowed to eat at will. Only if oral intake remained insufficient after 5 days, which was left to the opinion of the treating physician, PN could be initiated in this group.
Receives: Other: Oral Nutrition Protocol (ONP) group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. the Postoperative Length of Stay

    The primary outcome measure was the interval from surgery to discharge. Discharge means that the patient returns to his home.

    Measured: one month after surgery

Secondary outcomes (8)
  1. Successful Implementation Rate of the ONP in the Experimental Group

    Successful implementation of the ONP was achieved if the patient followed the protocol and did not need PN.

    Measured: 30 days postoperative

  2. Number of Administered PN

    Number of administered PN per group

    Measured: 30 days postoperative

  3. The Time to Resumption of Full Diet.

    The time to resumption of full diet between the two groups was compared.

    Measured: 30 days postoperative

  4. Patients With One or More Postoperative Complication.

    Number of patients with one or more postoperative complication were compared betweent the two groups.

    Measured: 30 days postoperative

  5. The Number of Postoperative Complications Per Patient.

    The number of postoperative complications per patient was compared between the two groups.

    Measured: 30 days postoperative

  6. Patients With a Catheter Related Bloodstream Infection

    Patients with a catheter related bloodstream infection were compared between the two groups

    Measured: 30 days postoperative

  7. The Type of Postoperative Complications.

    The type of postoperative complications (POCs) were compared between the two groups. The type of POCs were classified using the Clavien-Dindo Classification. Herein POCs were classified into 8 categories (1. Infection, 2. Fistula/leak, 3. Bleeding/hematoma, 4. Gastrointestinal, 5. Cardiopulmonary, 6. Neurologic, 7. pain and 8. Other) and stratified by their severity grade (Table 2). Per patient, multiple complications are possible.

    Measured: 30 days postoperative

  8. Severity Grade of Postoperative Complications.

    Severity grade of postoperative complications (POCs) was compared between the two groups. The severity grade of POCs were classified using the Clavien-Dindo Classification. Per patient, multiple complications are possible.

    Measured: 30 days postoperative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jan 2013 (estimated)
  2. Study startJan 2009
  3. Primary completionApr 2011
  4. Study completionNov 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
94 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01777126
Sponsor's protocol ID
ONP
Acronym
ONP
Status last verified
Jan 2011
First submitted
15 Jan 2013
Last updated
17 Jul 2014
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Oral Nutrition Protocol (ONP) group in people with Post Cystostomy, run by Universitaire Ziekenhuizen KU Leuven at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Jul 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 17 Jul 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

the Postoperative Length of Stay (time frame: one month after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in